Neuroimmune Response to Lipopolysaccharide

Phase 1

Completed

• Conditions: Healthy
• Interventions: Biological: Lipopolysaccharide

• Registration Number: NCT04233593
• Lead Sponsor: Yale University

Brief Summary

In this study, healthy adult volunteers will undergo two positron emission tomography (PET) scans using the radiotracer \[11C\]PBR28 which binds to the 18kDa translocator protein (TSPO). Approximately 3 hours prior to the second \[11C\]PBR28 PET scan, lipopolysaccharide (LPS; endotoxin) will be administered to evoke a robust neuroimmune response. Subjects will also undergo behavioral and cognitive testing. Vital signs, subjective response, and peripheral cytokine levels will be assayed periodically throughout the experimental session.

Specific aims: Quantify the magnitude of neuroimmune response after a classical immune stimulus.

Secondary aims: Quantify changes in cognitive function after a classical immune stimulus.

Hypothesis: Individuals will exhibit a robust whole-brain neuroimmune response and impaired cognitive function after LPS.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-03-25
• Study First Submitted: 2020-01-11
• Study First Submitted QC: 2020-01-16
• Study First Posted: 2020-01-18
• Primary Completion: 2021-08-17
• Study Completion: 2021-08-17
• Status Verified: 2022-06
• Last Update Submitted: 2022-07-14
• Last Update Posted: 2022-07-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

1. Medically-healthy male and female subjects able to read/write English

Read More

Exclusion Criteria

1. Subjects cannot meet DSM criteria for substance use disorder
2. Any psychiatric symptoms that could put the subject at risk by participating in the study including but not limited to suicidal or homicidal ideation, or suicide attempt within the last year
3. Pregnancy or breastfeeding;
4. Any current medical illness that could put the subjects at risk during the PET scan, or interfere with the PET or immunologic measures
5. Significant hepatocellular injury (as evidenced by AST or ALT levels greater than 5 times normal or a history of cirrhosis) will be exclusionary in order to reduce the risks associated with alcohol consumption
6. Subjects taking corticosteroids or other immunosuppressant drugs
7. Subjects with disorders affecting the brain, including but not limited to multiple sclerosis, history of stroke, brain tumors, intracranial bleeding, infection, or abscess.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
LPS Challenge	Lipopolysaccharide	Subjects will undergo one 120-minute \[11C\]PBR28 PET scan before and one scan 3-hours after LPS administration (1.0ng/kg; IV).

Primary Outcome Measures

Name	Time	Method
Baseline TSPO Availability	Before LPS administration (baseline)	Time-activity curves will be extracted from brain regions of interest and analyzed using multilinear analysis-1 (t\*=30) incorporating the metabolite-corrected arterial input function to yield \[11C\]PBR28 total volumes of distribution (VT) across brain regions.

Secondary Outcome Measures

Name	Time	Method
Alcohol Dependence Scale (ADS) - questionnaire	baseline	self-report questionnaire to determine severity of alcohol symptoms, 25 question multiple choice scale, range of 0-47 for a total score, with higher numbers indicating worse severity

Trial Locations

Locations (1)

Yale University; 🇺🇸 New Haven, Connecticut, United States